Adis Journals
Retifanlimab clinical summary.pdf (208.29 kB)
Download file

Retifanlimab: First Approval

Download (208.29 kB)
online resource
posted on 2023-05-16, 19:27 authored by Connie Kang



Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.



Retifanlimab (retifanlimab-dlwr; ZYNYZTM) is a programmed cell death 1 receptor–blocking antibody that is being developed by Incyte Corporation for the treatment of solid tumours, both as monotherapy and in combination with other agents. Retifanlimab recently received accelerated approval for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. This article summarizes the milestones in the development of retifanlimab leading to this first approval for Merkel cell carcinoma.

© Springer Nature Switzerland AG 2023


Usage metrics